Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06598462 · ClinicalTrials.gov registry record · Phase 2
A Study to Investigate the Efficacy and Safety of NSI-8226 in Adults With Eosinophilic Esophagitis
A Phase 2 study of Eosinophilic Esophagitis (EoE), sponsored by Uniquity One (UNI).
- Active
- Registry status
- Phase 2
- Development phase
- 184
- Enrollment target
- 20
- Study locations
NCT06598462 is a Phase 2 study of Eosinophilic Esophagitis (EoE) that is active but no longer recruiting, run by Uniquity One (UNI). The registered enrollment target is 184 participants, above the 108-participant average among 10 other Eosinophilic Esophagitis (EoE) trials with a reported enrollment target (70% higher). The trial reports 20 study locations across 13 states.
The verdict
NCT06598462, a Phase 2 study of Eosinophilic Esophagitis (EoE), is active but no longer recruiting, sponsored by Uniquity One (UNI).
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 184 participants
- Enrollment target
- 20
- Study locations
Study Summary
Phase 2 study to evaluate the safety, tolerability, PK, immunogenicity, and pharmacodynamics of solrikitug in adult participants with eosinophilic esophagitis.
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL Solrikitug Low Dose
- BIOLOGICAL Solrikitug Mid Dose
- BIOLOGICAL Solrikitug High Dose
Study Locations (20)
Arizona
- Research Site 1018 - Glendale
- Research Site 1018 - Peoria
- Research Site 1037 - Scottsdale
- Research Site 1003 - Tucson
California
- Research Site 1023 - Englewood
- Research Site 1005 - Irvine
- Research Site 1015 - San Diego
Florida
- Research Site 1040 - Inverness
- Research Site 1001 - Jacksonville
- Research Site 1049 - Miami
Alabama
- Research Site 1039 - Dothan
Colorado
- Research Site 1034 - Aurora
Connecticut
- Research Site 1027 - Cromwell
Idaho
- Research Site 1007 - Boise
Illinois
- Research Site 1048 - Glenview
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 184 participants |
| Start Date | 2024-10-16 |
| Est. Completion | 2027-08-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06598462
The ClinicalTrials.gov registry entry for NCT06598462 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 184 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 108-participant average among 10 other Eosinophilic Esophagitis (EoE) trials with a reported enrollment target (70% higher). The listed sponsor is Uniquity One (UNI), which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Eosinophilic Esophagitis (EoE) appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT06598462 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Arizona, California, Florida.
Frequently Asked Questions
What is clinical trial NCT06598462 about?
NCT06598462 is a clinical study titled "A Study to Investigate the Efficacy and Safety of NSI-8226 in Adults With Eosinophilic Esophagitis". Phase 2 study to evaluate the safety, tolerability, PK, immunogenicity, and pharmacodynamics of solrikitug in adult participants with eosinophilic esophagitis.
What is the current status of trial NCT06598462?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 184 participants. The study started on 2024-10-16. Estimated completion is 2027-08-31.
What conditions does trial NCT06598462 study?
This clinical trial studies the following conditions: Eosinophilic Esophagitis (EoE).
What interventions are being tested in trial NCT06598462?
The interventions under investigation include: Placebo (OTHER), Solrikitug Low Dose (BIOLOGICAL), Solrikitug Mid Dose (BIOLOGICAL), Solrikitug High Dose (BIOLOGICAL).
Who is sponsoring clinical trial NCT06598462?
This trial is sponsored by Uniquity One (UNI), which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06598462 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Eosinophilic Esophagitis (EoE)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
OBS in Adolescent and Adults With EOE: A Phase II, Randomized, Double-Blind, Placebo Controlled, Study With an Open Label Extension
COMPLETED · Phase 2
-
SOFEED: Six Food vs. One Food Eosinophilic Esophagitis Diet Study
COMPLETED · Phase 2
-
Surface EMG Testing on Swallowing in EoE Patients
RECRUITING
-
A U.S. Registry of Eosinophilic Esophagitis Pediatric, Adolescent and Adult Patients Treated With DUPIXENT® As Standard of Care
RECRUITING
-
Effect of Dupilumab on the Muscle Function of the Esophagus (food Pipe) in Participants with Eosinophilic Esophagitis (EoE)
RECRUITING · Phase 4
-
A Study of Dupilumab in Small Children With an Allergic Condition of the Esophagus (Food Pipe): Eosinophilic Esophagitis
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.